Triazine Affinity Ligands for Factor VIII Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying Factor VIII and von Willebrand's Factor from plasma or recombinant sources are complex, costly, and result in low yields due to instability and limited re-use of chromatography materials, making it difficult to achieve effective and cost-effective isolation.
Innovation Solution
Development of novel triazine-based compounds that act as affinity ligands, immobilized on support matrices, capable of selectively binding and eluting Factor VIII/von Willebrand's Factor from complex mixtures, including human plasma and recombinant fermentation supernatants, using a specific structure and linker configurations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If immunoaffinity chromatography is used for Factor VIII purification, then purification capability is improved, but material stability and reusability deteriorate
Solution Approach 1:
The patent creates a synthetic peptide copy (Lys8-FVIII) that mimics the binding properties of the native Factor VIII protein. This peptide-based ligand is immobilized on chromatography media, providing a stable, reusable alternative to protein-based immunoaffinity materials while maintaining high purification capability for vWF/FVIII complexes.
2Manufacturing precision
If complex purification procedures are used, then purification effectiveness is improved, but productivity and yield deteriorate
Solution Approach 1:
The patent extracts and utilizes the specific binding domain (Lys8 peptide sequence) from the larger Factor VIII protein structure. This isolated peptide element retains the essential binding function while eliminating the complexity and instability of the full protein, enabling simpler, more efficient chromatography procedures with higher yields.
3Strength
If protein-based affinity materials are used, then binding affinity is improved, but cost and stability deteriorate
Solution Approach 1:
The patent segments the Factor VIII protein into its essential functional component - the Lys8 peptide sequence. This segmented approach maintains the critical binding affinity for vWF/FVIII while dramatically reducing the complexity, cost, and instability associated with using complete protein-based affinity materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The triazine-based affinity ligands enable efficient and cost-effective purification of Factor VIII/von Willebrand's Factor, demonstrated by chromatography experiments showing high recovery and purity, addressing the limitations of existing purification methods.
Implementation Method 1
certain compounds, many of which are novel, are useful for affinity-based isolation of vWF/FVIII
Data Source
AI summary
For the separation, removal, isolation, purification, characterization, identification or quantification of Factor VIII, von Willebrand's Factor or a protein that is a analogue of either, an affinity adsorbent is used that is a compound of formula (II) wherein one X is N and the other is N, C—Cl or C—CN; A is a support matrix, optionally linked to the triazine ring by a spacer; Y is O, S or NR2; Z is O, S or N—R3; R2 and R3 are each H, C1-6 alkyl, C1-6 hydroxyalkyl, benzyl or &bgr;-phenylethyl; B and W are each an optionally substituted hydrocarbon linkage containing from 1 to 10 carbon atoms; D is H, OH or a primary amino, secondary amino, tertiary amino, quaternary ammonium, imidazole, guanidino or amidino group; or B-D is —CHCOOH—(CH2)3-4—NH2; and R7 is a group bearing a positive charge at neutral pH.